TW202328121A - 環狀磺醯胺核糖核苷酸還原酶(rnr)抑制劑及其用途 - Google Patents

環狀磺醯胺核糖核苷酸還原酶(rnr)抑制劑及其用途 Download PDF

Info

Publication number
TW202328121A
TW202328121A TW111134951A TW111134951A TW202328121A TW 202328121 A TW202328121 A TW 202328121A TW 111134951 A TW111134951 A TW 111134951A TW 111134951 A TW111134951 A TW 111134951A TW 202328121 A TW202328121 A TW 202328121A
Authority
TW
Taiwan
Prior art keywords
alkyl
pharmaceutically acceptable
tautomer
solvate
stereoisomer
Prior art date
Application number
TW111134951A
Other languages
English (en)
Chinese (zh)
Inventor
安東尼 B 平克頓
賈克斯 懋格
彥 範 鴻 張
瑞奇爾 珍奈特 埃爾頓
史蒂芬 陶德 梅爾
Original Assignee
美商無界生物公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商無界生物公司 filed Critical 美商無界生物公司
Publication of TW202328121A publication Critical patent/TW202328121A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
TW111134951A 2021-09-17 2022-09-15 環狀磺醯胺核糖核苷酸還原酶(rnr)抑制劑及其用途 TW202328121A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163245718P 2021-09-17 2021-09-17
US63/245,718 2021-09-17

Publications (1)

Publication Number Publication Date
TW202328121A true TW202328121A (zh) 2023-07-16

Family

ID=85603496

Family Applications (1)

Application Number Title Priority Date Filing Date
TW111134951A TW202328121A (zh) 2021-09-17 2022-09-15 環狀磺醯胺核糖核苷酸還原酶(rnr)抑制劑及其用途

Country Status (11)

Country Link
US (1) US20250002486A1 (cg-RX-API-DMAC7.html)
EP (1) EP4401728A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024534420A (cg-RX-API-DMAC7.html)
KR (1) KR20240101555A (cg-RX-API-DMAC7.html)
CN (1) CN118434417A (cg-RX-API-DMAC7.html)
AU (1) AU2022345092A1 (cg-RX-API-DMAC7.html)
CA (1) CA3231660A1 (cg-RX-API-DMAC7.html)
IL (1) IL311458A (cg-RX-API-DMAC7.html)
MX (1) MX2024003258A (cg-RX-API-DMAC7.html)
TW (1) TW202328121A (cg-RX-API-DMAC7.html)
WO (1) WO2023043923A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112023002453A2 (pt) 2020-08-12 2023-05-02 Boundless Bio Inc Composições de agente de via de estresse de replicação e métodos para tratar câncer
EP4587437A1 (en) * 2022-09-13 2025-07-23 Boundless Bio, Inc. Cyclic sulfonamide ribonucleotide reductase (rnr) inhibitors and uses thereof
EP4770642A2 (en) * 2023-09-01 2026-07-08 Boundless Bio, Inc. Ribonucleotide reductase (rnr) compositions and methods of use

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2594799A (en) * 1998-02-11 1999-08-30 Du Pont Pharmaceuticals Company Novel cyclic sulfonamide derivatives as metalloproteinase inhibitors
WO2016189877A1 (en) * 2015-05-27 2016-12-01 Kyorin Pharmaceutical Co., Ltd. Urea derivative or pharmacologically acceptable salt thereof
ES2982299T3 (es) * 2016-05-31 2024-10-15 Taiho Pharmaceutical Co Ltd Compuestos de sulfonamida o sal de los mismos como inhibidores de ribonucleótido reductasa para el tratamiento del cáncer
TWI748142B (zh) * 2017-11-29 2021-12-01 日商大鵬藥品工業股份有限公司 抗腫瘤劑
AU2018377036B2 (en) * 2017-11-29 2022-04-14 Taiho Pharmaceutical Co., Ltd. Sulfonamide compounds and use thereof
MA56065A (fr) * 2019-05-29 2022-04-06 Taiho Pharmaceutical Co Ltd Polythérapie anticancéreuse mettant en oeuvre un composé de sulfonamide et un immunomodulateur
EP4301735A4 (en) * 2021-03-02 2025-05-21 Boundless Bio, Inc. Ribonucleotide reductase (rnr) inhibitors and uses thereof

Also Published As

Publication number Publication date
MX2024003258A (es) 2024-04-05
EP4401728A1 (en) 2024-07-24
IL311458A (en) 2024-05-01
US20250002486A1 (en) 2025-01-02
KR20240101555A (ko) 2024-07-02
WO2023043923A1 (en) 2023-03-23
JP2024534420A (ja) 2024-09-20
CA3231660A1 (en) 2023-03-23
EP4401728A4 (en) 2025-08-06
CN118434417A (zh) 2024-08-02
AU2022345092A1 (en) 2024-04-04

Similar Documents

Publication Publication Date Title
AU2023275712A1 (en) Pyridine checkpoint kinase 1 (chk1) inhibitors and uses thereof
AU2012284540B2 (en) TRPV4 antagonists
TW202313588A (zh) 檢測點激酶1(chk1)抑制劑及其用途
JP7159215B2 (ja) Pge2レセプター調節剤としてのピリミジン誘導体
KR101345497B1 (ko) 설폰아미드 유도체
CA2960275A1 (en) Smyd inhibitors
BRPI0720196A2 (pt) Composto ou um sal farmaceuticamente aceitável do mesmo, e, composição farmacêutica
TW200904813A (en) Compounds
EP3774739B1 (en) Fused cyclic urea derivatives as crhr2 antagonist
EP4401728A1 (en) Cyclic sulfonamide ribonucleotide reductase (rnr) inhibitors and uses thereof
CN102127096A (zh) 三氮唑并吡啶和三氮唑并吡嗪化合物及其组合物和应用
JP2020520356A (ja) Pge2レセプター調節剤としてのフェニル誘導体
KR20240035830A (ko) 피리디논 mk2 저해제 및 이의 용도
EA028828B1 (ru) ПРОИЗВОДНЫЕ 5,6,7,8-ТЕТРАГИДРОПИРАЗИНО[2,3-c]ПИРИДАЗИНА И ИХ ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ ОНКОЛОГИЧЕСКИХ ЗАБОЛЕВАНИЙ
US20240158383A1 (en) Ribonucleotide reductase (rnr) inhibitors and uses thereof
EP4402134A1 (en) Sulfamide ribonucleotide reductase (rnr) inhibitors and uses thereof
CA3237762A1 (en) 1h-benzo[b]azepin-2(3h)-one compounds, compositions and methods of treating cancer
TW202421160A (zh) 環狀磺醯胺核糖核苷酸還原酶(rnr)抑制劑及其用途
TWI423974B (zh) 三氮唑並吡啶和三氮唑並吡嗪化合物及其組合物和應用
HK40057478B (en) Hpk1 inhibitors and methods of using same
EA051928B1 (ru) Пиридиновые ингибиторы киназы 1 контрольной точки (chk1) и их применение
HK40043109B (en) Fused cyclic urea derivatives as crhr2 antagonist
HK40043109A (en) Fused cyclic urea derivatives as crhr2 antagonist
TW201305153A (zh) 三唑並吡啶和三唑並吡嗪化合物及其組合物和應用
NZ754629B2 (en) Novel bicyclic bromodomain inhibitors